GlassScriptPhysician profile
Brett Michael Weinstock
NPI 1356753883
$9,542.56
in general payments reported to CMS, 2019-2025
36 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $607 · 2021: $917 · 2022: $1,607 · 2023: $1,784 · 2024: $1,697 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,190 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,189.79 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $4,471.05 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Sight Sciences, INC. | $532.22 | 2020-2024 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $476.81 | 2022-2025 | Xiidra, Miebo, Infuse |
| New World Medical,INC. | $430.90 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Johnson & Johnson Surgical Vision, INC. | $429.16 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $402.02 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $308.89 | 2019-2025 | |
| Allergan, INC. | $279.01 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $207.49 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $206.66 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $195.00 | 2022-2025 | Tyrvaya |
| Ocular Therapeutix, INC. | $172.50 | 2019-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $154.69 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $144.69 | 2022 | |
| Omeros Corporation | $140.94 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.58 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $110.71 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $109.02 | 2021-2022 | |
| Amgen INC. | $97.40 | 2024-2025 | Tepezza |
| Dompe US, INC. | $85.88 | 2021-2025 | Oxervate |
| Merz North America, INC. | $67.97 | 2019-2020 | |
| Horizon Therapeutics Plc | $63.44 | 2022-2023 | Tepezza |
| Rxsight INC | $57.20 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $39.15 | 2021 | |
| Harrow Eye, LLC | $37.56 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $27.08 | 2020-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Rayner Intraocular Lenses Limited | $17.29 | 2022 | |
| Eusa Pharma (US) LLC | $16.30 | 2022 | |
| Recordati_rare_diseases_inc. | $16.30 | 2022 | |
| Merz Pharmaceuticals, LLC | $15.60 | 2024 | Xeomin |
| Shire North American Group INC | $14.94 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $14.78 | 2021 | |
| Eyepoint US, INC. | $13.38 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.28 | 2024 | Purified Cortrophin Gel |
| Tearlab Corp | $13.27 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.